Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 6, 1997, Pages 697-703

  Sturgill, Marc G ^a,b   Grasing, Kenneth W ^a   Rosen, Raymond C ^a   Thomas, T J ^a   Kulkarni, Gayathri D ^a   Trout, J Richard ^c   Maines, Margaret ^a   Seibold, James R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Anxiety; Catecholamines; Metabolism; Pharmacokinetics; Vital signs; Yohimbine

Indexed keywords

ADRENALIN; NORADRENALIN; YOHIMBINE;

ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; FEMALE; HUMAN; MALE; MOOD; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA;

ADULT; AFFECT; ANXIETY; AREA UNDER CURVE; DOUBLE-BLIND METHOD; EPINEPHRINE; HALF-LIFE; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; PERSONALITY INVENTORY; YOHIMBINE;

EID: 0030814722     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199706000-00001     Document Type: Article

References (25)

1. 2-adrenoceptors. Pharmacol Rev 1983;35: 143-80.
2. 2-Adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine. Br J Pharmacol 1993;108:927-32.
3. Grunhaus L, Tiongco D, Zelnik T, Regel P, Hollingsworth PM, Smith CB. Intravenous yohimbine: selective enhancer of norepinephrine and cortisol secretion and systolic blood pressure in humans. Clin Neuropharmacol 1989;12:106-14.
4. Hedner T, Edgar B, Edvinsson L, Hedner J, Persson B, Petterson A. Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. Eur J Clin Pharmacol 1992;43:651-6.
5. Yohimbine for male sexual dysfunction. Med Lett 1994;36:115-6.
6. Henaur SA, Gillespie HK, Hollister LE. Yohimbine and the model anxiety state. J Clin Psychiatry 1984;45:512-5.
7. Sachs GS, Pollack MH, Brotman AW, Farhadi AM, Gelenberg AJ. Enhancement of ECT benefit by yohimbine. J Clin Psychiatry 1986;47:508-10.
8. 2-adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 1982;30:2033-41.
9. Berlan M, Galitzky J, Riviere D, et al. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and nonobese women, Int J Obesity 1991;15:305-15.
10. 2-Antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest 1988;18:587-94.
11. Morales A, Surridge DHC, Marshall PG, Fenemore J. Nonhormonal pharmacological treatment of organic impotence. J Urol 1982;128:45-7.
12. Lacomblez L, Bensimon G, Isnard F, Diquet B, Lecrubier Y, Puech AJ. Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine. Clin Pharmacol Ther 1989;45:241-51.
13. Lecrubier Y, Puech AJ, Des Laurels A. Favorable effects of yohimbine on clomipramine-induced orthostatic hypotension: a double-blind study. Br J Clin Pharmacol 1981;12:90-4.
14. Morales A, Condra M, Owen JA, Surridge DH, Fenemore J, Harris C. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987;137:1168-72.
15. Susset JG, Tessier CD, Wincze J, Bansal S, Malhotra C, Schwacha MG. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 1989;141:1360-3.
16. Reid K, Morales A, Harris C, Surridge DHC, Condra M, Owen J. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 1987;2:421-3.
17. Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology 1994;44:732-6.
18. Owen JA, Nakatsu SL, Fenemore J, Condra M, Surridge DHC, Morales A. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol 1987;32:577-82.
19. Guthrie SK, Hariharan M, Grunhaus LJ. Yohimbine bioavailability in humans. Eur J Clin Pharmacol 1990;39:409-11.
20. Hariharan M, Guthrie S, Kindt EK, VanNoord T, Grunhaus LJ. Liquid chromatographic coulometric assay and preliminary pharmacokinetics of yohimbine in man. J Liquid Chromatogr 1991;14:351-64.
21. Plasma catecholamine methodology book. Bedford, MA: ESA, 1984.
22. Gupta RN, Steiner M, Lew M. Determination of unconjugated 3-methoxy-4-hydroxyphenylglycol by liquid chromatography for monitoring inhibition of monoamine oxidase activity in plasma. Clin Chem 1987;33:2078-80.
23. Lorr M, McNair DM. Profile of Mood States Bi-Polar Form (POMS-BI) manual. San Diego, CA: Educational and Industrial Testing Service, 1984/1988.
24. Le Verge R, Le Corre P, Chevanne F. Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. J Chromatogr 1992;574:283-92.
25. Bagheri H, Picault P, Schmitt L, Houin G, Berlan M, Montastruc JL. Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic anti-depressants. Br J Clin Pharmacol 1994;37:93-6.